Vivo Opportunity Fund Holdings and Affiliates' Ownership in SAB Biotherapeutics, Inc.

Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC have filed a Schedule 13G regarding their ownership in SAB Biotherapeutics, Inc. The filing indicates that these entities collectively own a significant portion of the company's securities, including Common Stock and Series B Preferred Stock. The Series B Preferred Stock, Enrollment Warrants, and Data Release Warrants contain provisions that prevent conversion or exercise into Common Stock if it would result in the holder or its affiliates obtaining more than 9.99% of the company's voting securities. The filing also includes a Joint Filing Agreement, signed by Kevin Dai, the Managing Member of the general partners of these entities, acknowledging their responsibility for the accuracy and completeness of the information provided.